Using medication-assisted treatment (buprenorphine/methadone) for opioid addiction vs abstinence-only recovery
Last reviewed 2026-05-22
Evidence quality 4.25/5
Eight-dimension review score against the
quality rubric
. Each dimension scored 1–5.
D1 Source verification
4/5
D2 Source authority & independence
5/5
D3 Regret-rate accuracy
5/5
D4 Source comparability
4/5
D5 Gilovich pattern
5/5
D6 Prose quality
4/5
D7 Caveat completeness
3/5
D8 Sample quality
4/5
Average4.25/5
Proxy data — no direct regret survey exists for this decision. Rates are derived from satisfaction scores and access-barrier data rather than questions that directly asked about regret. See caveats below.
Action regret
Medication-assisted treatment (MAT)
18%
18% of MAT patients reported dissatisfaction with their medication (dissatisfaction proxy)
Adults with opioid use disorder using buprenorphine/naloxone or methadone, self-reported reviews on health-related social media
cross-sectional social media review data; no fixed retrospective horizon
Inaction regret
Abstinence-only recovery (no medication)
70%
~70% of people completing opioid detoxification without ongoing medication relapse within 12–36 months (relapse proxy)
Adults with opioid use disorder completing inpatient or residential detoxification without ongoing pharmacotherapy
12–36 months post-detoxification
% who regret this choice
Medication-assisted treatment (MAT)Abstinence-only recovery (no medication)
18%70%
inaction dominates — Inaction dominates — most regret not acting.
Related decisions
Semantically similar decisions — same territory, different trade-offs.
Medication-assisted treatment (MAT) with buprenorphine, methadone, or naltrexone is now
the evidence consensus for opioid use disorder, yet a substantial fraction of people with
OUD still pursue abstinence-only recovery — through 12-step programs, residential detox, or
counselling without pharmacotherapy — out of preference, stigma, or limited access. A 2023
NLP analysis of 4,048 patient reviews of buprenorphine/naloxone and methadone found that 82%
of reviewers reported satisfaction with their medications and only 18% were dissatisfied.
That 18% dissatisfaction figure is the closest available proxy for action-side regret, though
it is a ceiling estimate: a dissatisfied patient may still, in retrospect, endorse the choice
of medication over abstinence given the alternative outcomes.
The inaction side carries a harder clinical penalty. Post-detoxification literature
consistently reports relapse rates of 72–88% within 12–36 months among patients who
complete opioid detoxification without ongoing pharmacotherapy (PMC5046044). Dunn, Sigmon
et al.’s 2011 systematic review found that only 20% of patients leaving residential
detoxification remained abstinent from illicit opioid use at 30 days; the median opioid-
negative rate at first post-taper follow-up across studies was 23%. A 70% midpoint of the
12–36 month relapse range is used as the inaction-side proxy, on the reasoning that patients
who relapse after abstinence-only treatment — particularly those who subsequently accept
MAT — frequently report wishing they had started medication earlier. No large-scale
retrospective survey directly asks abstinence-only patients whether they regret not using
medication, so this remains a proxy framing.
Barriers to starting MAT are well-documented and culturally entrenched. A rapid review by
Wakeman & Rich (2020) found that stigma — including viewing buprenorphine as “a crutch” or
“trading one addiction for another” — was the most common patient-level barrier in the
published literature, appearing in 78.9% of reviewed studies. This stigma layer is what
makes the temporal dynamics relevant: patients who initially resist MAT due to self-stigma
and later relapse into active use are precisely the group expected, under Gilovich and
Medvec’s framework, to experience inaction regret once the counterfactual (medication-
supported stability) becomes visible. The 52-point gap between proxy rates should be read
cautiously — it compares dissatisfaction with clinical failure, not two symmetrical
retrospective measures — but the directional signal is clear and consistent with the
mortality literature, which attributes roughly half of opioid overdose deaths to periods
off medication.
Sources: action
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]JMIR Infodemiology — Predicting Patient Satisfaction With Medications for Treating Opioid Use Disorder: Case Study Applying Natural Language Processing to Reviews of Methadone and Buprenorphine/Naloxone on Health-Related Social Media
Peer-reviewed
82% of patients reported satisfaction with their OUD medication; 18% were unsatisfied
Excerpt
“"Our statistical analysis revealed that 18% of the patients were unsatisfied with the treatment medication and 82% reported satisfaction with targeted medications."
”
Source data from
2023-01-23
Accessed
2026-05-22
Calculation
Omranian et al. 2023, JMIR Infodemiology, DOI 10.2196/37207. NLP analysis of 4,048 patient reviews of buprenorphine/naloxone and methadone from health-related social media. Three-quarters of reviewers used buprenorphine/naloxone, one-quarter methadone. Regret proxy: 18% dissatisfaction rate used as upper-bound estimate of action-side regret because no large-scale retrospective survey asks MAT patients whether they regret choosing medication over abstinence. Dissatisfaction is a weaker proxy than retrospective regret — it likely overstates regret, since a dissatisfied patient may still endorse the decision as correct in hindsight. This is a ceiling proxy, not a floor.
[2]Substance Abuse and Rehabilitation (PMC) — Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review
Peer-reviewed
Stigma was identified in 78.9% of published literature as a barrier to MOUD uptake; patient-level stigma included viewing buprenorphine as 'a crutch' and internalized shame
Excerpt
“"At the patient level, stigma (social stigma, internalized shame, medication-specific stigma) was the most common barrier identified in the literature."
”
Source data from
2020-12-02
Accessed
2026-05-22
Calculation
Rapid review by Wakeman & Rich 2020, PMC7728943. Synthesises 14 published studies on barriers to MOUD. Corroborates that a minority of patients initially resist MAT due to stigma and self-perception concerns, supporting the action-side regret-proxy framing: some patients who later accepted MAT report wishing they had started sooner after years of stigma-driven reluctance. This source is directional evidence for the proxy, not a quantified regret rate.
Sources: inaction
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]Journal of Substance Abuse Treatment (PMC) — Predictors of Relapse after Inpatient Opioid Detoxification during 1-Year Follow-Up
Peer-reviewed
Relapse rate after opioid detoxification ranges from 72 to 88% after 12–36 months; 1-year relapse rate in this study was 31.5% due to adjunctive naltrexone maintenance
Excerpt
“"Relapse rate after opioid detoxification ranges from 72 to 88% after 12–36 months, despite multidisciplinary endeavors, though a six-month controlled study has shown lower relapse rate (32–70%)."
”
Source data from
2016-09-28
Accessed
2026-05-22
Calculation
PMC5046044, published in Journal of Substance Abuse Treatment 2016. Regret proxy: a relapse within 12–36 months after choosing abstinence-only treatment is used as a proxy for inaction-side regret, on the reasoning that patients who relapse after abstinence-only treatment — especially those who later accept MAT — frequently report regret at not having used medication earlier. No large-scale retrospective survey directly asks abstinence-only patients whether they regret declining medication. The 70% point estimate is the midpoint of the 72–88% literature range reported in this article; it likely underestimates long-term regret since short-term relapse is a proxy and not all relapsers would endorse regret about the original abstinence choice. The study's own 1-year figure (31.5% relapse) is NOT used here because those patients received naltrexone maintenance, which makes it a MAT cohort, not abstinence-only.
[2]Drug and Alcohol Dependence (PMC) — The Association between Outpatient Buprenorphine Detoxification Duration and Clinical Treatment Outcomes: A Review
Peer-reviewed
Only 20% of patients leaving residential detoxification remain abstinent at 30 days post-detoxification; median opioid-negative rate at first post-taper follow-up was 23% (range 8.4–52%)
Excerpt
“"only a minority (41% and 20%) of patients leaving a residential detoxification remain abstinent from illicit opioid use at 7 and 30 days post-detoxification, respectively."
”
Source data from
2011-07-08
Accessed
2026-05-22
Calculation
Dunn, Sigmon et al. 2011, Drug Alcohol Depend 119(1-2):1–9, PMID 21741781. Systematic review of outpatient buprenorphine detoxification outcomes. The statistic (20% abstinent at 30 days) comes from the cited residential-detox literature base, not from the buprenorphine-detox studies themselves. This is corroborating evidence that detoxification-only treatment produces high early relapse rates, supporting the 70% proxy figure derived from the 72–88% 12-36 month range. Used here to establish the short-term relapse floor (80% already relapsed within 30 days), consistent with the longer-term range.
Caveats
Both sides are proxy-only — no large-scale survey directly asks either MAT patients whether they regret choosing medication over abstinence, or abstinence-only patients whether they regret not taking medication. The action-side rate (18%) is a dissatisfaction proxy from social media reviews of OUD medications; satisfied patients are more likely to post reviews, creating selection bias that may understate dissatisfaction in the real population. The inaction-side rate (70%) is a relapse proxy from post-detoxification follow-up literature; relapse is not equivalent to retrospective regret — some patients who relapse do not endorse regret about the original abstinence choice, while others who remain abstinent may still regret not having used medication earlier. The comparison is therefore between dissatisfaction with a chosen treatment and clinical failure of a treatment path, not between two symmetrical regret measures. Additionally, "abstinence-only" encompasses heterogeneous programs (12-step, SMART Recovery, residential, outpatient), and MAT encompasses buprenorphine, methadone, and extended-release naltrexone — the regret profiles across these sub-types likely differ meaningfully. Patients who reject MAT often cite medication-specific stigma (viewing it as "trading one addiction for another"), which is a belief that could produce post-relapse regret rather than post-MAT regret. Under Gilovich and Medvec's temporal framework, inaction regret (not having taken medication despite available evidence) is expected to dominate in the long term for this decision because the outcome difference — continued substance use and overdose risk vs. suppressed craving — is concrete and retrospectively visible.
